Phase 3 N=523 Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831
Schizophrenia · Schizophreniform Disorder · Bipolar I Disorder
Primary: Incidence of Adverse Events — 314 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=807 Study Comparing Trifarotene Cream, 0.005% To AKLIEF ® (Trifarotene 0.005% Cream) In The Treatment Of Acne Vulgaris
Acne Vulgaris
Primary: Primary Change in Inflammatory Lesion Counts — -72.86; -78.83; -34.12 Percent change
Phase 3 N=544 This Was a Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS).
Hidradenitis Suppurativa
Primary: Percentage of Participants With Hidradenitis Suppurativa Clinical Response (HiSCR50) — 45.0; 41.8; 33.7 Percentage of participants — p=0.0070
Phase 3 N=601 Phase III Palbociclib With Endocrine Therapy vs. Capecitabine in HR+/HER2- MBC With Resistance to Aromatase Inhibitors
Metastatic Breast Cancer
Primary: Progression-Free Survival (PFS) — 7.3; 9.4; 7.5; 10 month
Phase 3 N=1,105 Compare Two Copper IUDs: Mona Lisa NT Cu380 Mini and ParaGard
Healthy Women · Female Contraception
Primary: Pregnancy Rate of Mona Lisa Copper IUD Over 3 Years — 1.86 Pearl Index = Num preg per 100 person yr
Phase 3 N=119 A Study to Determine the Safety and Efficacy of NT-501 in Macular Telangiectasia Type 2 - Protocol B
Macular Telangiectasia Type 2
Primary: The Rate of Change in the Area of EZ Area of Loss From Baseline Through Month 24 — 0.111; 0.160 mm^2 — p=0.0186
Phase 3 N=77 Behavioral or Solifenacin Therapy for Urinary Symptoms in Parkinson Disease
Overactive Bladder · Parkinson Disease
Primary: ICIQ-OAB Questionnaire — 5.5; 5.8 score on a scale
Phase 3 N=120 A Study to Determine the Safety and Efficacy of NT-501 in Macular Telangiectasia Type 2 - Protocol A
Macular Telangiectasia Type 2 (MacTel)
Primary: The Rate of Change in the Area of EZ Area of Loss From Baseline Through Month 24 — 0.075; 0.166 mm^2 — p=<0.0001
Phase 3 N=6,102 A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults
Seasonal Influenza
Primary: Geometric Mean Titer (GMT) of Anti-Hemagglutinin (HA) Antibodies at Day 29, as Measured by Hemagglutination Inhibition (HAI) Assay for Vaccine-matched Influenza A and B…
Phase 3 N=5 A Study of TAK-625 for the Treatment of Progressive Familial Intrahepatic Cholestasis (PFIC)
Progressive Familial Intrahepatic Cholestasis (PFIC)
Primary: Change in the Average Morning Itch Reported Outcome (ItchRO) (Observer Instrument [Obs]) Severity Score Between Baseline and the Average of Week 15 Through Week 26…
Phase 3 N=32 Intravenous Immunoglobulin (IVIG, Bioven) Efficacy and Safety in Chronic Primary Immune Thrombocytopenia (ITP) in Adults
Primary Immune Thrombocytopenia
Primary: Part (Percent) of Patients With Response (R) — 24 Participants
Phase 3 N=57 Aspirin in Young Psychotic Patients
Psychosis · Acute Psychosis · Schizophrenia
Primary: Neurological Soft Signs — 6.96; 7.04 score on a scale — p=0.863
Phase 3 N=676 Сlinical Trial of Efficacy and Safety of Prospekta in the Treatment of Post-COVID-19 Asthenia.
Post-acute COVID-19 Syndrome
Primary: Change in the Mean FSS Score. — 46.4; 45.9; 29.9; 31.9 score on a scale — p=0.0016
Phase 3 N=300 Study of Mirogabalin for Central Neuropathic Pain
Central Neuropathic Pain
Primary: Change From Baseline in the Weekly Average Daily Pain Score (ADPS) at Week 14 Following Administration With Mirogabalin or Placebo — -1.23; -0.52 units on a scale…
Phase 3 N=487 Efficacy and Safety of Delgocitinib Cream in Adults With Moderate to Severe Chronic Hand Eczema
Chronic Hand Eczema
Primary: Number of Participants With IGA-CHE TS at Week 16 — 64; 16 Participants — p=0.006